News and Announcements
Suda (ASX: SUD) Approaches the World Health Organisation to Add ArTiMist to Its Guidelines
- Published May 14, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- SUDA Pharmaceuticals of Perth, Australia, announced on 7 May 2018, its intention to approach WHO for the inclusion of its spray ArTiMist in the guidelines for treatment of malaria.
- Subsequent to the Phase III trials of the product, it has proved to be more effective than quinine and quinidine, the conventional treatment options for severe malaria.
- The company’s decision to approach WHO was prompted by the potential licensee of the product and SUDA’s efforts are on to find out if any further information is required by WHO for including ArTiMist in its guidelines.
Australian pharmaceutical giant, SUDA (ASX: SUD), announced on 7 May 2018, its intention to persuade WHO for including ArTiMist to its list of guidelines concerning treatment plan for malaria among children. This decision of the Perth-based company comes in the wake of Phase III trials of the drug wherein it was proved as being superior to Quinine,
the conventional treatment option for malaria.
WHO recently released statistics wherein it revealed that mortality rate of severe malaria – particularly the cerebral version – had touched 100% and for this figure to fall to 10% levels, effective treatment plan and supportive care was a must. The WHO report also observed that in case of severe cases of malaria being admitted to a hospital/clinic, death occurred within a few hours of the patient having been admitted. In such a situation, the need of the hour was that of a highly effective anti-malarial drug as part of the therapy.
As per the current guidelines of WHO, antimalarial treatment comprises of two classes of medicines, the more widespread of which is quinine and quinidine. However, Phase III trial of ArTiMist proved that it was more effective than intravenous quinine in treating this medical condition.
SUDA’s decision to approach WHO to seek approval for ArTiMist was prompted by the potential licensee who would market it in future. Prior to approaching WHO, SUDA intends to find out if any additional data needs to be submitted for ArTiMist to be included in the guidelines.
About SUDA Pharmaceuticals (ASX: SUD)
SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
